Omeros Corporation (NASDAQ:OMER) traded down 1.2% on Wednesday . The stock traded as low as $11.18 and last traded at $11.26, with a volume of 133,787 shares traded. The stock had previously closed at $11.40.

Several equities research analysts have weighed in on the company. FBR & Co reissued an “outperform” rating and set a $38.00 price objective on shares of Omeros Corporation in a research note on Wednesday, June 29th. WBB Securities reissued a “buy” rating and set a $75.00 price objective on shares of Omeros Corporation in a research note on Tuesday, June 14th. Maxim Group assumed coverage on Omeros Corporation in a research report on Saturday, June 4th. They set a “buy” rating for the company. Cantor Fitzgerald assumed coverage on Omeros Corporation in a research report on Thursday, June 2nd. They set a “buy” rating and a $21.00 target price for the company. Finally, Wedbush restated an “outperform” rating and set a $62.00 target price on shares of Omeros Corporation in a research report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $38.22.

The firm’s 50-day moving average price is $11.05 and its 200 day moving average price is $12.38. The company’s market cap is $439.88 million.

Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.11. The firm had revenue of $7.40 million for the quarter, compared to the consensus estimate of $8.79 million. The firm’s quarterly revenue was up 1797.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.51) earnings per share. On average, equities research analysts anticipate that Omeros Corporation will post ($1.76) earnings per share for the current fiscal year.

In other news, VP Marcia S. Kelbon sold 15,900 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $9.94, for a total value of $158,046.00. Following the completion of the sale, the vice president now owns 179,497 shares of the company’s stock, valued at $1,784,200.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Several large investors have added to or reduced their stakes in the company. Bank of Montreal Can raised its stake in Omeros Corporation by 52.0% in the fourth quarter. Bank of Montreal Can now owns 1,327,706 shares of the biopharmaceutical company’s stock valued at $20,885,000 after buying an additional 454,055 shares during the last quarter. Mutual of America Capital Management LLC raised its stake in Omeros Corporation by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 116,171 shares of the biopharmaceutical company’s stock valued at $1,827,000 after buying an additional 694 shares during the last quarter. Brown Advisory Inc. raised its stake in Omeros Corporation by 44.6% in the fourth quarter. Brown Advisory Inc. now owns 529,699 shares of the biopharmaceutical company’s stock valued at $8,332,000 after buying an additional 163,306 shares during the last quarter. California State Teachers Retirement System raised its stake in Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock valued at $1,103,000 after buying an additional 1,249 shares during the last quarter. Finally, Nationwide Fund Advisors raised its stake in Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 45,145 shares during the last quarter.

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL), which is replacement surgery, to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.